Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Wegovy, derived from semaglutide, acts as a GLP-1 receptor agonist, mimicking the GLP-1 hormone to reduce appetite by increasing insulin secretion and signaling feelings of fullness to the brain, he says
It's administered weekly and suits adults with a BMI of 30 or above, or 27 or above with a weight-related health condition
Some researchers and obesity medicine specialists recommend even higher targets of up to 2.0 g/kg of ideal body weight for patients who are actively resistance training during GLP-1 therapy
*HSA/FSA accepted
These results are available for review at Saxendas official website
US$ 20.96
US$ 27.36
US$ 23.48
US$ 20.54
